In conclusion, we have firstly demonstrated that the combination treatment of BBR and OPCs promoted the anti-tumorigenic effects in CRC possibly through the inhibition of cellular apoptosis by regulating the expression of MYB in the PI3K-Akt signaling pathway. The gene discussed is AKT1; the disease is colorectal carcinoma.